Novartis
NEWS
The primary endpoint of the trial was improving overall response rate at Day 28 with Jakafi compared to the best available therapy.
It was a busy week for clinical trial announcements. Here’s a look.
What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others?
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
The approval of Beovu was based on findings from the Phase III HAWK and HARRIER clinical trials, in which Novartis’ drug demonstrated non-inferiority versus Eylea in mean change in best-corrected visual acuity at 48 weeks.
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
It was another busy week for clinical trials. Here’s a look.
In a Phase III trial, Cosentyx showed a significant and clinically meaningful reduction in disease activity for patients versus placebo.
Swiss pharma giant Novartis has partnered with tech giant Microsoft and launched its Novartis AI innovation lab as a means to leverage data and artificial intelligence to transform drug discovery and development.
JOBS
IN THE PRESS